The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Thromboembolic Adverse Events After Use of Recombinant Human Coagulation Factor VIIa
Abstract
CONTEXT: The US Food and Drug Administration (FDA) licensed recombinant human coagulation factor VIIa (rFVIIa) on March 25, 1999, for bleeding in patients with hemophilia A or B and inhibitors to factors VIII or IX. Use in patients without hemophilia has been increasing since licensure. OBJECTIVE: To review serious thromboembolic adverse events (AEs) reported to the FDA's Adverse Event Reporting System (AERS). DESIGN, SETTING, AND PATIENTS: The AERS database was reviewed from March 25, 1999, through December 31, 2004, for thromboembolic AE reports with rFVIIa. The AERS database includes US and non-US spontaneous AE reports from both approved (specific indications for patients with hemophilia) and unlabeled uses. It also includes serious AEs in patients enrolled in postlicensure clinical trials who received rFVIIa. Manufacturer reporting to FDA is mandatory, but primary notification from clinicians and others to FDA or manufacturers is voluntary for spontaneous reports; therefore, AERS underrepresents actual event occurrences. MAIN OUTCOME MEASURE: Reported thromboembolic events occurring in patients administered rFVIIa. RESULTS: A total of 431 AE reports for rFVIIa were found, of which 168 reports described 185 thromboembolic events. Seventeen events occurred in patients with hemophilia and 59 occurred in patients enrolled in postlicensure trials. Unlabeled indications accounted for 151 of the reports, most with active bleeding (n = 115). Reported AEs were thromboembolic cerebrovascular accident (n = 39), acute myocardial infarction (n = 34), other arterial thromboses (n = 26), pulmonary embolism (n = 32), other venous thromboses (including deep vein thrombosis) (n = 42), and clotted devices (n = 10). In 36 (72%) of 50 reported deaths, the probable cause of death was the thromboembolic event. In 144 patients with timing information, 73 events (52%) occurred in the first 24 hours after the last dose (30 events within 2 hours). Sixty-four reports (38%) noted concomitant use of hemostatic agents. Most reports lacked sufficient information to evaluate potential dosage associations. CONCLUSIONS: Most reported thromboembolic AEs followed the use of rFVIIa for unlabeled indications and occurred in arterial and venous systems, often resulting in serious morbidity and mortality. Analysis of the relationship between AEs and rFVIIa is hindered by concomitant medications, preexisting medical conditions, confounding by indication, and inherent limitations of passive surveillance. Randomized controlled trials are needed to establish the safety and efficacy of rFVIIa in patients without hemophilia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Cell-based Model of Hemostasis
Monroe, D., & Hoffman, M. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615947 · Cited by 1,542
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A. (2007) · Stroke · doi:10.1161/01.str.0000254499.46122.22 · Cited by 1,034
International Classification of Diseases, Ninth Revision
National Cancer Institute (2020) · Definitions · doi:10.32388/bd1nux · Cited by 888
Platelet activity of high‐dose factor VIIa is independent of tissue factor
Monroe, D. M., Hoffman, M., Oliver, J. A., & Roberts, H. R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.4463256.x · Cited by 534
?Off-license? use of recombinant activated factor VII
Ghorashian, S. (2004) · Blood Reviews · doi:10.1016/j.blre.2003.12.003 · Cited by 75
Cited by
Authors/Task Force Members, Bassand, J.-P., Hamm, C. W., Ardissino, D., Boersma, E., Budaj, A., Fernandez-Aviles, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,849
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
Practice Bulletin No. 183: postpartum hemorrhage
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002351 · Cited by 1,406
Spahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage
Mayer, S. A. (2007) · Stroke · doi:10.1161/01.str.0000254499.46122.22 · Cited by 1,034
Management of bleeding and coagulopathy following major trauma: an updated European guideline
Spahn, D. R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2013) · Critical Care · doi:10.1186/cc12685 · Cited by 977
Management of bleeding following major trauma: an updated European guideline
Rossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Hunt, B. J., Komadina, R., Nardi, G., Neugebauer, E., et al. (2010) · Critical Care · doi:10.1186/cc8943 · Cited by 818
Rossaint, R., Afshari, A., Bouillon, B., Cerny, V., Cimpoesu, D., Curry, N., Duranteau, J., Filipescu, D., Grottke, O., Grønlykke, L., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04327-7 · Cited by 776
Frontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Safety of Recombinant Activated Factor VII in Randomized Clinical Trials
Levi, M., Levy, J. H., Andersen, H. F., & Truloff, D. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006221 · Cited by 677
Rapezzi, C., Biagini, E., & Branzi, A. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm498 · Cited by 595
Prevention and Treatment of Major Blood Loss
Mannucci, P. M., & Levi, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067742 · Cited by 494
Universal definition of perioperative bleeding in adult cardiac surgery
Dyke, C., Aronson, S., Dietrich, W., Hofmann, A., Karkouti, K., Levi, M., Murphy, G. J., Sellke, F. W., Shore-Lesserson, L., von Heymann, C., et al. (2014) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2013.10.070 · Cited by 453
Management of bleeding following major trauma: a European guideline
Spahn, D. R., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Gordini, G., Stahel, P. F., Hunt, B. J., Komadina, R., Neugebauer, E., et al. (2007) · Critical Care · doi:10.1186/cc5686 · Cited by 437
Hemostasis and thrombosis in patients with liver disease: The ups and downs
Lisman, T., Caldwell, S. H., Burroughs, A. K., Northup, P. G., Senzolo, M., Stravitz, R. T., Tripodi, A., Trotter, J. F., Valla, D.-C., & Porte, R. J. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.01.042 · Cited by 360
Hauser, C. J., Boffard, K., Dutton, R., Bernard, G. R., Croce, M. A., Holcomb, J. B., Leppaniemi, A., Parr, M., Vincent, J.-L., Tortella, B. J., et al. (2010) · Journal of Trauma: Injury, Infection & Critical Care · doi:10.1097/ta.0b013e3181edf36e · Cited by 346
Blood Coagulation: Hemostasis and Thrombin Regulation
Tanaka, K. A., Key, N. S., & Levy, J. H. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bcc9c · Cited by 342
The Role of Tissue Factor and Factor VIIa in Hemostasis
Mackman, N. (2009) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e31819bceb1 · Cited by 335
Pathophysiology and Treatment of Coagulopathy in Massive Hemorrhage and Hemodilution
Bolliger, D., Görlinger, K., Tanaka, K. A., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181f22b5a · Cited by 325
Treatment of Warfarin-Associated Intracerebral Hemorrhage: Literature Review and Expert Opinion
Aguilar, M. I., Hart, R. G., Kase, C. S., Freeman, W. D., Hoeben, B. J., García, R. C., Ansell, J. E., Mayer, S. A., Norrving, B., Rosand, J., et al. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60970-1 · Cited by 306
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
Gill, R., Herbertson, M., Vuylsteke, A., Olsen, P. S., von Heymann, C., Mythen, M., Sellke, F., Booth, F., & Schmidt, T. A. (2009) · Circulation · doi:10.1161/circulationaha.108.834275 · Cited by 280
Rahe-Meyer, N., Pichlmaier, M., Haverich, A., Solomon, C., Winterhalter, M., Piepenbrock, S., & Tanaka, K. A. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep089 · Cited by 261
Prediction and management of bleeding in cardiac surgery
DESPOTIS, G., AVIDAN, M., & EBY, C. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03412.x · Cited by 99
Metadata
- Authors
- O’Connell, K. A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-01-18
- Volume
- 295
- Issue
- 3
- Pages
- 293
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2140699529
- Cited by
- 671
- References
- 5
- FWCI
- 51.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.